News | Computed Tomography (CT) | July 03, 2018

Decision by largest U.S. insurance provider means HeartFlow Analysis now covered for more than 75 percent of Americans

HeartFlow Announces New Commercial Coverage With UnitedHealthcare

July 3, 2018 — HeartFlow Inc. announced that UnitedHealthcare now covers the HeartFlow FFRct Analysis, extending access to their 45 million beneficiaries. With this new coverage, more than 235 million people in the United States now have access to the HeartFlow Analysis.

The non-invasive technology uses a coronary computed tomography angiogram (CTA) to create a personalized 3-D model of the heart and simulate blood flow in order to help clinicians diagnose and treat people with suspected coronary artery disease (CAD).

In a new coverage decision, UnitedHealthcare also chose to adopt the medical policy for coronary CTA from eviCore, an evidence-based specialty benefits management company. The policy allows for the use of a coronary CTA as a first-line test for symptomatic individuals, removing the need for a standard stress test prior to conducting a coronary CTA. In addition, the HeartFlow Analysis is now approved to further assess coronary disease seen on a coronary CTA that is of uncertain physiological significance.

CAD affects 16.8 million Americans and develops when the coronary arteries narrow, reducing blood flow to the heart and potentially causing chest pain (angina), heart attack (myocardial infarction) and death.

Clinicians diagnosing someone with suspected CAD want to know as definitively as possible if the individual has a significant blockage in their coronary arteries. They also want to know the impact of that blockage on blood flow so they can best determine which treatment pathway is appropriate (e.g., medical management, stenting or coronary artery bypass grafting).

Data from a patient’s non-invasive coronary CTA are securely uploaded from the hospital’s system to the cloud. HeartFlow leverages deep learning to create a personalized, digital 3-D model of the patient’s coronary arteries. The HeartFlow Analysis then uses powerful computer algorithms to solve millions of complex equations to simulate blood flow and assess the impact of blockages on coronary blood flow. The service is provided via a secure online interface to offer actionable information to enable clinicians to determine the optimal course of treatment.

For more information: www.heartflow.com


Related Content

News | FDA

April 16, 2026 — Royal Philips has received U.S. Food and Drug Administration 510(k) clearance for the Philips Spectral ...

Time April 20, 2026
arrow
News | Radiology Imaging

April 7, 2026 — Onvida Health and Siemens Healthineers have entered a 10-year Value Partnership¹ designed to bring the ...

Time April 09, 2026
arrow
News | Computed Tomography (CT)

April 2, 2026 — Nano-X Imaging Ltd. recently announced its U.S.-based subsidiary, Nanox Impact Inc., has signed a new ...

Time April 08, 2026
arrow
News | SNMMI

The Society of Nuclear Medicine and Molecular Imaging's (SNMMI) 2026 Annual Meeting will take place May 30–June 2 in Los ...

Time April 07, 2026
arrow
News | Teleradiology

April 1, 2026 — Premier Radiology Services has acquired Global Imaging Solutions (GLOBIS), a leading teleradiology group ...

Time April 03, 2026
arrow
News | Radiology Business

March 31, 2026 — Radon Medical Imaging, a medical imaging equipment maintenance and repair services company, has has ...

Time March 31, 2026
arrow
News | Radiology Imaging

March 26, 2026 — GE HealthCare has announced a renewed research collaboration with Stanford Medicine Department of ...

Time March 30, 2026
arrow
News | Cardiac Imaging

March 28, 2026 — When Ashley Perlow felt a sharp pain shoot across her chest and into both wrists, she didn't think it ...

Time March 30, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

March 25, 2026 A Penn Medicine–led team has developed a first‑of‑its‑kind artificial intelligence system that interprets ...

Time March 26, 2026
arrow
News | FDA

March 24, 2026 — MARS Bioimaging, a New Zealand–headquartered medical device company, has received U.S. Food and Drug ...

Time March 25, 2026
arrow
Subscribe Now